HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
by on Tuesday, September 11th, 2012 | No Comments
Condition: Metastatic Melanoma
Intervention: Drug: vemurafenib + HD IL-2
Sponsors: Prometheus Laboratories; Prometheus Laboratories
Active, not recruiting – verified September 2012
Read the original post: HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma